Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,655 across all filing types
Latest filing 2022-04-22 Management Reports
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
2021年度监事会工作报告
Management Reports Classification · 95% confidence The document is titled '2021 年度监事会工作报告' which translates to '2021 Supervisory Board Work Report' of Shenzhen BGI Genomics Co., Ltd. It details the supervisory board's activities, including oversight of financial conditions, compliance with laws, internal controls, related party transactions, and other governance matters for the fiscal year 2021. The document contains substantive content about the supervisory board's work, financial oversight, and governance, rather than just an announcement or summary. It is not an annual report (10-K) but a specific report from the supervisory board, which is a type of management or governance report. Given the detailed supervisory board work and oversight content, this fits best under Management Reports (MDA), which include management's detailed explanation of financial results, business trends, and outlook. The document is over 6000 characters, so it is not a mere announcement. Therefore, the classification is MDA with high confidence.
2022-04-22 Chinese
独立董事关于第三届董事会第七次会议相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is an opinion from independent directors regarding the proposal to reappoint the audit firm for the 2022 fiscal year. It references regulatory rules related to independent directors and audit firms, and it is a pre-approval opinion for a board meeting agenda item about the audit firm appointment. The document does not contain actual audit results or financial statements, nor is it a full audit report. It is related to board/management information about audit firm appointment, which is typically classified under Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication, so it is not RPA. It is not a certification or regulatory filing either. Therefore, the best fit is MANG.
2022-04-22 Chinese
2021年度独立董事述职报告（曹亚）
Management Reports Classification · 95% confidence The document is titled '年度独立董事述职报告' which translates to 'Annual Independent Director's Work Report'. It details the independent director's activities, attendance at board meetings, opinions on company matters, committee work, investigations, investor protection efforts, and training during the 2021 fiscal year. The content is a detailed report on the independent director's duties and performance over the year, not an announcement or a brief summary. It does not contain financial statements or earnings data, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a regulatory filing or certification. The document fits best as a Management Report (MDA) because it provides management-level explanation and oversight details related to governance and company operations from the perspective of an independent director.
2022-04-22 Chinese
中信证券股份有限公司关于深圳华大基因股份有限公司2021年度募集资金存放与使用情况的专项核查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "专项核查报告" (special verification report) by CITIC Securities regarding the 2021 annual fundraising funds deposit and usage of Shenzhen BGI Genomics Co., Ltd. It details the amount of funds raised, their deposit, management, usage, investment projects, and compliance with regulatory requirements. The document includes detailed financial figures related to fundraising, usage, and investment projects, as well as audit and verification opinions from CITIC Securities and an accounting firm. It is a standalone audit/verification report focused on the use of fundraising proceeds, not a full annual report or earnings release. It does not present comprehensive company financial statements or management discussion of overall financial results, but rather a specialized audit on fundraising funds usage. Therefore, it fits the definition of an Audit Report / Information (AR). The document length is sufficient and contains substantive financial data and audit conclusions, not merely an announcement or certification letter. FY 2021
2022-04-22 Chinese
关于续聘2022年度审计机构的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the reappointment of the audit firm Ernst & Young Hua Ming for the fiscal year 2022. It discusses the audit firm's qualifications, independence, and the approval process by the board, audit committee, and supervisory board. It does not contain the audit report itself or detailed financial statements but rather the company's decision and procedural details about continuing the audit engagement. The document length is 4263 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this document is best classified as an Audit Report / Information (AR) type, as it relates specifically to audit matters but is not a full annual report or the audit report itself. Confidence is high due to the clear focus on audit firm reappointment and related disclosures. FY 2022
2022-04-22 Chinese
2021年度募集资金存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2021年度募集资金存放与使用情况的专项报告" which translates to a "Special Report on the Deposit and Use of Raised Funds for the Year 2021". It details the issuance of shares to specific investors, the amount of funds raised, the management and use of these funds, including investment projects, cash management, and compliance with regulatory requirements. The document includes detailed tables showing the allocation and usage of the raised funds, agreements with banks and sponsors, and audit confirmations. It is a comprehensive report focused on the company's capital raising activities and the specific use of those funds during the fiscal year 2021. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document is not an announcement of a report publication, nor is it a general regulatory filing or an annual report. Therefore, the appropriate classification is CAP with high confidence.
2022-04-22 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.